Selective CYP17 inhibition with abiraterone acetate (AA) in castration resistant prostate cancer (CRPC): the Royal Marsden Hospital experience

被引：0
|
作者：
Reid, A. [1 ]
Attard, G. [1 ]
Oommen, N. Babu [1 ]
Olmos, D. [1 ]
Fong, P. [1 ]
Molife, R. [1 ]
Dowsett, M. [2 ]
Lee, G. [3 ]
Molina, A. [3 ]
De-Bono, J. S. [1 ]
机构：
[1] Royal Marsden NHS Fdn Trust, Drug Dev Unit, London, England
[2] Acad Dept Biochem, Royal Marsden NHS Fdn Trust, London, England
[3] Cougar Biotechnol Inc, Los Angeles, CA USA
来源：
EJC SUPPLEMENTS | 2008年 / 6卷 / 12期
关键词：
D O I：
10.1016/S1359-6349(08)71958-X
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：12 / 12
页数：1
相关论文
共 50 条
  • [21] Association of biomarkers with cardiac events during abiraterone acetate treatment in castration resistant prostate cancer (CRPC)
    Zanardi, Silvia
    Campora, Sara
    Puntoni, Matteo
    Piccininno, Marco
    Piccardo, Arnoldo
    Naserl, Mehrdad Shoushtari Zadeh
    Defferrarl, Carlotta
    Biscaldi, Ennio
    Antonucci, Giancarlo
    Ricci, Damiano
    Mori, Marco
    De Consi, Andrea
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [22] Initial experience with abiraterone acetate in patients with castration-resistant prostate cancer
    Beardo-Villar, P.
    Ledo-Cepero, M. J.
    Gavira-Moreno, R.
    Soto-Delgado, M.
    Soto-Vittalba, J.
    Alvarez-Ossorio, J. L.
    Juarez-Soto, A.
    ACTAS UROLOGICAS ESPANOLAS, 2014, 38 (05): : 339 - 345
  • [23] Abiraterone acetate in castration-resistant prostate cancer
    Iacovelli, Roberto
    Palazzo, Antonella
    Procopio, Giuseppe
    Gazzaniga, Paola
    Cortesi, Enrico
    ANTI-CANCER DRUGS, 2012, 23 (03) : 247 - 254
  • [24] CYP17 blockade by abiraterone: further evidence for frequent continued hormone-dependence in castration-resistant prostate cancer
    J E Ang
    D Olmos
    J S de Bono
    British Journal of Cancer, 2009, 100 : 671 - 675
  • [25] CYP17 blockade by abiraterone: further evidence for frequent continued hormone-dependence in castration-resistant prostate cancer
    Ang, Je
    Olmos, D.
    de Bono, J. S.
    BRITISH JOURNAL OF CANCER, 2009, 100 (05) : 671 - 675
  • [26] Androgen receptor (AR) mutations in patients (pts) with castration-resistant prostate cancer (CRPC) with and without prior abiraterone acetate (AA) treatment
    Rathkopf, Dana E.
    Smith, Matthew R.
    Antonarakis, Emmanuel S.
    Ryan, Charles J.
    Berry, William R.
    Shore, Neal D.
    Liu, Glenn
    Higano, Celestia
    Alumkal, Joshi J.
    Hauke, Ralph
    Tutrone, Ronald
    Saleh, Mansoor
    Maneval, Edna Chow
    Thomas, Shibu
    Ricci, Deborah
    Yu, Margaret K.
    de Boer, Carla J.
    Trinh, Angela
    Kheoh, Thian
    Bandekar, Rajesh
    Scher, Howard I.
    CANCER RESEARCH, 2015, 75
  • [27] PROSABI: Prospective multi-centre study of prognostic factors in castration resistant prostate cancer (CRPC) patients treated with abiraterone acetate (AA)
    Lorente Estelles, D.
    Puente, J.
    Medina, A.
    Lozano Mejorada, R.
    Rivera, L.
    Pacheco, M. I.
    Saez, M. I.
    Piulats Rodriguez, J. M.
    Fernandez Parra, E. M.
    Borrega Garcia, P.
    Perez Valderrama, B.
    Gallardo Diaz, E.
    Villatoro, R.
    Morales Barrera, R.
    Vazquez Estevez, S.
    Pinto Marin, A.
    Contreras Ibanez, J. A.
    Romero Laorden, N.
    Castro Marcos, E.
    ANNALS OF ONCOLOGY, 2017, 28
  • [28] A multicenter population-based experience with abiraterone acetate (AA) in patients with metastatic castration resistant prostate cancer (mCRPC)
    Clayton, Ravinder
    Heng, Daniel Yick Chin
    Wu, Jackson S. Y.
    Zielinski, Rob
    North, Scott A.
    Emmenegger, Urban
    Hotte, Sebastien J.
    Al-Shamsi, Humaid Obaid
    Chen, Leo
    Eigl, Bernhard J.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [29] Weight change analysis in advanced castration resistant prostate cancer (CRPC) patients treated with Abiraterone Acetate (AA) single agent and in combination with steroids
    Bianchini, D.
    Zivi, A.
    Attard, G.
    Mezynski, J.
    Cassidy, A.
    Sandhu, S.
    Hunt, J.
    Sheridan, L.
    Thompson, E.
    de Bono, J. S.
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2011, 78 : S23 - S23
  • [30] Association of CYP17A1 single nucleotide polymorphism (SNP) with response to abiraterone acetate (AA) in metastatic castration-resistant prostate cancer (mCRPC).
    Zhang, Ben Miming
    Binder, Moritz
    Costello, Brian Addis
    Quevedo, Fernando
    Kohli, Manish
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
12345